Literature DB >> 21966890

Use of the Montreal global definition as an assessment of quality of life in reflux disease.

R A Sawaya1, A Macgill, H P Parkman, F K Friedenberg.   

Abstract

According to the Montreal Consensus Group's classification, gastroesophageal reflux disease develops when the reflux of stomach contents causes troublesome symptoms and/or complications such as esophagitis. The characteristic gastroesophageal reflux disease symptoms included in this statement are retrosternal burning and regurgitation. Troublesome is meant to imply that these symptoms impact on the well-being of affected individuals; in essence, quality of life (QOL). Whether heartburn and regurgitation symptoms would be characterized as more troublesome in those with confirmed pathologic acid reflux was determined. A second purpose was to assess how well troublesome scores correlated with the results of a validated, disease-specific QOL instrument. Subjects who underwent esophagogastroduodenoscopy (EGD) with 48-hour wireless esophageal pH testing off proton pump inhibitor therapy were interviewed. Esophagitis on EGD or pH < 4.0 for ≥4.5% of time over the 2-day period was considered positive for acid reflux. Assessment of how troublesome their symptoms of heartburn and regurgitation were made using separate 0-100 visual analog scales (VAS). Subjects were then asked to complete the Quality of Life in Reflux and Dyspepsia (QOLRAD) 25-item questionnaire. Sixty-seven patients (21 males, 46 females) with mean age 47.8 ± 15.6 years were identified. Forty (59.7%) had an EGD or pH study positive for acid reflux. Overall 35/40 (87.5%) complained of either heartburn or regurgitation. There was no difference (P= 0.80) in heartburn VAS troublesome ratings for those with (54.0 ± 43.9) and without (56.7 ± 37.6) confirmed acid reflux. The same was true for regurgitation VAS troublesome ratings (P= 0.62). Likewise, mean QOLRAD scores did not differ between those with and without confirmed acid reflux by pH or EGD (4.5 ± 1.7 vs. 4.3 ± 1.7; P= 0.61). There was a moderately strong inverse correlation between patient self-rated VAS troublesome scores for both heartburn and regurgitation with each dimension (emotional distress, sleep disturbance, eating problems, physical/social functioning, and vitality) of the QOLRAD (P < 0.05 for all comparisons). In regression analysis, both heartburn and regurgitation troublesome ratings were associated with the overall QOLRAD score independent of pH data, frequency of reflux episodes, age, and gender. Use of the term troublesome in the Montreal Consensus Group classification is supported by our findings. It correlates well with the results of a validated disease-specific QOL instrument. Use of heartburn and regurgitation VAS may serve as accurate measures of the burden of reflux disease on patients. It is likely that these scales will not have sufficient discriminate value to identify individuals with pathologic acid reflux from those with negative studies.
© 2011 Copyright the Authors. Journal compilation © 2011, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.

Entities:  

Mesh:

Year:  2011        PMID: 21966890      PMCID: PMC3252470          DOI: 10.1111/j.1442-2050.2011.01271.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  27 in total

Review 1.  Quality of life assessment in gastro-oesophageal reflux disease.

Authors:  E J Irvine
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

2.  Reliability of 24-hour home esophageal pH monitoring in diagnosis of gastroesophageal reflux.

Authors:  S Mattioli; V Pilotti; M Spangaro; W F Grigioni; R Zannoli; V Felice; A Conci; G Gozzetti
Journal:  Dig Dis Sci       Date:  1989-01       Impact factor: 3.199

3.  The predictive value of history in dyspepsia.

Authors:  T Johannessen; H Petersen; P M Kleveland; J H Dybdahl; A K Sandvik; E Brenna; H Waldum
Journal:  Scand J Gastroenterol       Date:  1990-07       Impact factor: 2.423

4.  The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease.

Authors:  P Moayyedi; A T Axon
Journal:  Am J Gastroenterol       Date:  1999-11       Impact factor: 10.864

5.  There are no reliable symptoms for erosive oesophagitis and Barrett's oesophagus: endoscopic diagnosis is still essential.

Authors:  B Avidan; A Sonnenberg; T G Schnell; S J Sontag
Journal:  Aliment Pharmacol Ther       Date:  2002-04       Impact factor: 8.171

Review 6.  The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease.

Authors:  Joshua J Ofman
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864

Review 7.  Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs.

Authors:  J Dent; D Armstrong; B Delaney; P Moayyedi; N J Talley; N Vakil
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

8.  Symptomatic gastroesophageal reflux: incidence and precipitating factors.

Authors:  O T Nebel; M F Fornes; D O Castell
Journal:  Am J Dig Dis       Date:  1976-11

9.  Symptoms in gastro-oesophageal reflux disease.

Authors:  A G Klauser; N E Schindlbeck; S A Müller-Lissner
Journal:  Lancet       Date:  1990-01-27       Impact factor: 79.321

10.  Effects of esomeprazole treatment for gastroesophageal reflux disease on quality of life in 12- to 17-year-old adolescents: an international health outcomes study.

Authors:  Thirumazhisai Gunasekaran; Vasundhara Tolia; Richard B Colletti; Benjamin D Gold; Barry Traxler; Marta Illueca; Joseph A Crawley
Journal:  BMC Gastroenterol       Date:  2009-11-18       Impact factor: 3.067

View more
  3 in total

1.  Surgical cure of primary hyperparathyroidism ameliorates gastroesophageal reflux symptoms.

Authors:  James Norman; Douglas Politz; Jose Lopez; Deva Boone; Alexander Stojadinovic
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

2.  Population-based assessment of heartburn in urban Black Americans.

Authors:  F K Friedenberg; K Makipour; A Palit; S Shah; V Vanar; J E Richter
Journal:  Dis Esophagus       Date:  2012-12-13       Impact factor: 3.429

Review 3.  Measuring response in the gastrointestinal tract in systemic sclerosis.

Authors:  Dinesh Khanna; Vivek Nagaraja; Heather Gladue; William Chey; Mark Pimentel; Tracy Frech
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.